Haleon plc (NYSE:HLN – Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 18,140,000 shares, an increase of 6.8% from the December 31st total of 16,990,000 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average trading volume of 6,580,000 shares, the days-to-cover ratio is currently 2.8 days.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on HLN shares. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.
Check Out Our Latest Stock Report on Haleon
Haleon Stock Performance
Hedge Funds Weigh In On Haleon
A number of institutional investors have recently bought and sold shares of the business. FMR LLC boosted its stake in Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after acquiring an additional 3,046,841 shares during the period. Douglas Lane & Associates LLC raised its holdings in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after acquiring an additional 161,865 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after acquiring an additional 1,026,939 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Haleon by 13.5% during the 4th quarter. Van ECK Associates Corp now owns 3,509,400 shares of the company’s stock worth $33,480,000 after acquiring an additional 418,609 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.
Haleon Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
- Five stocks we like better than Haleon
- How to Invest in Biotech Stocks
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Insider Trading – What You Need to Know
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- High-Yield Dividend King PepsiCo Offers Value Too Good to Ignore
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.